Clarivate Plc Q2 2026 Earnings Call Summary
Clarivate Plc outlined its Value Creation Plan (VCP) during the second quarter of 2026, focusing on transitioning from transactional to recurring subscription revenue. A key strategic move is the divestiture of the Life Sciences & Healthcare segment, which aims to streamline operations and focus capital on Academia & Government and Intellectual Property markets. The company emphasized leveraging its curated datasets with agentic AI to enhance customer workflows. Management expects sequential improvement in organic growth for recurring revenue through 2026 into 2027, projecting a pro forma revenue mix of about 92% from subscriptions post-divestiture. Clarivate anticipates returning IP segment growth by year-end and plans to use LS&H divestiture proceeds for debt reduction. A $269 million non-cash impairment charge was recorded in Q2 due to the LS&H agreement, with an additional one-time cost of around $70 million expected at closing. Foreign exchange fluctuations also impacted adjusted EBITDA by $7 million.
Tickers: $NVDA